170 related articles for article (PubMed ID: 35868102)
21. Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines.
So MK; Jeong TD; Lim W; Moon BI; Paik NS; Kim SC; Huh J
Breast Cancer; 2019 Jul; 26(4):510-519. PubMed ID: 30725392
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of pathogenic variants and variants of unknown significance in patients at high risk of breast cancer: A systematic review and meta-analysis of gene-panel data.
van Marcke C; Collard A; Vikkula M; Duhoux FP
Crit Rev Oncol Hematol; 2018 Dec; 132():138-144. PubMed ID: 30447919
[TBL] [Abstract][Full Text] [Related]
23. Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.
Batalini F; Peacock EG; Stobie L; Robertson A; Garber J; Weitzel JN; Tung NM
Breast Cancer Res; 2019 Sep; 21(1):107. PubMed ID: 31533767
[TBL] [Abstract][Full Text] [Related]
24. Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer.
Rosenberg SM; Sepucha K; Ruddy KJ; Tamimi RM; Gelber S; Meyer ME; Schapira L; Come SE; Borges VF; Golshan M; Winer EP; Partridge AH
Ann Surg Oncol; 2015 Nov; 22(12):3809-15. PubMed ID: 25930247
[TBL] [Abstract][Full Text] [Related]
25. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
Cragun D; Weidner A; Tezak A; Clouse K; Pal T
Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
[TBL] [Abstract][Full Text] [Related]
26. Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer.
Chen B; Zhang G; Li X; Ren C; Wang Y; Li K; Mok H; Cao L; Wen L; Jia M; Li C; Guo L; Wei G; Lin J; Li Y; Zhang Y; Han-Zhang H; Liu J; Lizaso A; Liao N
Aging (Albany NY); 2020 Feb; 12(4):3140-3155. PubMed ID: 32091409
[TBL] [Abstract][Full Text] [Related]
27. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
[TBL] [Abstract][Full Text] [Related]
28. Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer.
Elsayegh N; Webster RD; Gutierrez Barrera AM; Lin H; Kuerer HM; Litton JK; Bedrosian I; Arun BK
Cancer Med; 2018 Jun; 7(6):2718-2726. PubMed ID: 29733510
[TBL] [Abstract][Full Text] [Related]
29. Clinical management among individuals with variant of uncertain significance in hereditary cancer: A systematic review and meta-analysis.
Makhnoon S; Bednar EM; Krause KJ; Peterson SK; Lopez-Olivo MA
Clin Genet; 2021 Aug; 100(2):119-131. PubMed ID: 33843052
[TBL] [Abstract][Full Text] [Related]
30. Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors.
Graves KD; Peshkin BN; Halbert CH; DeMarco TA; Isaacs C; Schwartz MD
Breast Cancer Res Treat; 2007 Sep; 104(3):321-9. PubMed ID: 17066320
[TBL] [Abstract][Full Text] [Related]
31. Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: variant reclassification and surgical decisions.
Murray ML; Cerrato F; Bennett RL; Jarvik GP
Genet Med; 2011 Dec; 13(12):998-1005. PubMed ID: 21811163
[TBL] [Abstract][Full Text] [Related]
32. Classification of BRCA2 Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay.
Hu C; Susswein LR; Roberts ME; Yang H; Marshall ML; Hiraki S; Berkofsky-Fessler W; Gupta S; Shen W; Dunn CA; Huang H; Na J; Domchek SM; Yadav S; Monteiro ANA; Polley EC; Hart SN; Hruska KS; Couch FJ
Clin Cancer Res; 2022 Sep; 28(17):3742-3751. PubMed ID: 35736817
[TBL] [Abstract][Full Text] [Related]
33. Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer.
Kurian AW; Li Y; Hamilton AS; Ward KC; Hawley ST; Morrow M; McLeod MC; Jagsi R; Katz SJ
J Clin Oncol; 2017 Jul; 35(20):2232-2239. PubMed ID: 28402748
[TBL] [Abstract][Full Text] [Related]
34. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
35. Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer.
Hamilton JG; Genoff MC; Salerno M; Amoroso K; Boyar SR; Sheehan M; Fleischut MH; Siegel B; Arnold AG; Salo-Mullen EE; Hay JL; Offit K; Robson ME
Breast Cancer Res Treat; 2017 Apr; 162(2):297-306. PubMed ID: 28150129
[TBL] [Abstract][Full Text] [Related]
36. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Domchek SM; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Pichert G; Van t'veer L; Tung N; Weitzel JN; Couch FJ; Rubinstein WS; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Schildkraut J; Blum JL; Rebbeck TR
JAMA; 2010 Sep; 304(9):967-75. PubMed ID: 20810374
[TBL] [Abstract][Full Text] [Related]
37. Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing.
Chang J; Seng S; Yoo J; Equivel P; Lum SS
Ann Surg Oncol; 2019 Oct; 26(10):3389-3396. PubMed ID: 31342386
[TBL] [Abstract][Full Text] [Related]
38. Contribution of germline mutations in cancer predisposition genes to tumor etiology in young women diagnosed with invasive breast cancer.
Rummel SK; Lovejoy L; Shriver CD; Ellsworth RE
Breast Cancer Res Treat; 2017 Aug; 164(3):593-601. PubMed ID: 28503720
[TBL] [Abstract][Full Text] [Related]
39. Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing.
Cummings S; Roman SS; Saam J; Bernhisel R; Brown K; Lancaster JM; Usha L
J Ovarian Res; 2021 Apr; 14(1):61. PubMed ID: 33926482
[TBL] [Abstract][Full Text] [Related]
40. Genetic Counseling, Screening and Risk-Reducing Surgery in Patients with Primary Breast Cancer and Germline BRCA Mutations: Unmet Needs in Low- and Middle-Income Countries.
Moukadem HA; Al Masry A; Atwani RW; Kreidieh F; Khalil LE; Saroufim R; Daouk S; Dalle IA; El Saghir NS
Eur J Breast Health; 2022 Jan; 18(1):16-20. PubMed ID: 35059587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
